170 related articles for article (PubMed ID: 18435429)
61. Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model.
Howdon DDH; Lomas JRS; Paulden M
Value Health; 2019 Aug; 22(8):891-897. PubMed ID: 31426930
[TBL] [Abstract][Full Text] [Related]
62. Use of evidence in economic decision models: practical issues and methodological challenges.
Cooper NJ; Sutton AJ; Ades AE; Paisley S; Jones DR;
Health Econ; 2007 Dec; 16(12):1277-86. PubMed ID: 18034447
[TBL] [Abstract][Full Text] [Related]
63. Are There Scenarios When the Use of Non-Placebo-Control Groups in Experimental Trial Designs Increase Expected Value to Society?
Uyei J; Braithwaite RS
Med Decis Making; 2016 Jan; 36(1):20-30. PubMed ID: 25977361
[TBL] [Abstract][Full Text] [Related]
64. Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs.
Baker SG; Heidenberger K
Med Decis Making; 1989; 9(1):14-25. PubMed ID: 2492068
[TBL] [Abstract][Full Text] [Related]
65. An investment appraisal approach to clinical trial design.
Backhouse ME
Health Econ; 1998 Nov; 7(7):605-19. PubMed ID: 9845254
[TBL] [Abstract][Full Text] [Related]
66. Optimal clinical trial design using value of information methods with imperfect implementation.
Willan AR; Eckermann S
Health Econ; 2010 May; 19(5):549-61. PubMed ID: 19399753
[TBL] [Abstract][Full Text] [Related]
67. The cost-benefit of a randomized trial to a health care organization.
Hornberger J; Eghtesady P
Control Clin Trials; 1998 Apr; 19(2):198-211. PubMed ID: 9551284
[TBL] [Abstract][Full Text] [Related]
68. Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.
Kent S; Briggs A; Eckermann S; Berry C
Int J Technol Assess Health Care; 2013 Oct; 29(4):435-42. PubMed ID: 24290337
[TBL] [Abstract][Full Text] [Related]
69. Randomized controlled trial and economic evaluation.
Jain S; Arora NK
Indian J Pediatr; 2000 May; 67(5):363-8. PubMed ID: 10885210
[TBL] [Abstract][Full Text] [Related]
70. Designing a cost-effective clinical trial.
Hornberger JC; Brown BW; Halpern J
Stat Med; 1995 Oct; 14(20):2249-59. PubMed ID: 8552901
[TBL] [Abstract][Full Text] [Related]
71. A View from the Bridge: Health Economic Evaluation - A Value-Based Framework?
Briggs A
Health Econ; 2016 Dec; 25(12):1499-1502. PubMed ID: 27870333
[No Abstract] [Full Text] [Related]
72. Efficient treatment allocation in 2 × 2 multicenter trials when costs and variances are heterogeneous.
Lemme F; van Breukelen GJP; Candel MJJM
Stat Med; 2018 Jan; 37(1):12-27. PubMed ID: 28948651
[TBL] [Abstract][Full Text] [Related]
73. HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?
Garattini L; Padula A
Eur J Health Econ; 2020 Feb; 21(1):1-5. PubMed ID: 31440857
[No Abstract] [Full Text] [Related]
74. Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics.
Eckermann S
Front Public Health; 2022; 10():1085319. PubMed ID: 36582386
[TBL] [Abstract][Full Text] [Related]
75. Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials.
Coyle D; Davies L; Drummond MF
Int J Technol Assess Health Care; 1998; 14(1):135-44. PubMed ID: 9509801
[TBL] [Abstract][Full Text] [Related]
76. Conducting rapid, relevant research: lessons learned from the My Own Health Report project.
Glasgow RE; Kessler RS; Ory MG; Roby D; Gorin SS; Krist A
Am J Prev Med; 2014 Aug; 47(2):212-9. PubMed ID: 24953520
[TBL] [Abstract][Full Text] [Related]
77. Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
Diao G; Zeng D; Ibrahim JG; Rong A; Lee O; Zhang K; Chen Q
J Biopharm Stat; 2017; 27(6):933-944. PubMed ID: 28296570
[TBL] [Abstract][Full Text] [Related]
78. Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression.
Heath A; Manolopoulou I; Baio G
Med Decis Making; 2019 May; 39(4):346-358. PubMed ID: 31161867
[No Abstract] [Full Text] [Related]
79. Focusing technology assessment using medical decision theory.
Phelps CE; Mushlin AI
Med Decis Making; 1988; 8(4):279-89. PubMed ID: 3185180
[TBL] [Abstract][Full Text] [Related]
80. Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research.
Meltzer D
J Health Econ; 2001 Jan; 20(1):109-29. PubMed ID: 11148867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
